At a glance
What is it—and why does it matter?
Liraglutide is described as an analogue of glucagon-like peptide 1 (GLP-1). As a GLP-1 receptor agonist, liraglutide triggers GLP-1 receptor signaling via Gs-dependent adenylyl cyclase activation. The study used random assignment and double-blinding to compare liraglutide versus placebo in a high cardiovascular-risk type 2 diabetes population. The pregnancy section provides a risk statement derived from animal reproduction studies and a conditional-use recommendation during pregnancy based on benefit–risk judgment.
Each sentence above is copied from a published claim presentation. The links open its evidence record.
Victoza and Saxenda are separate products with different target doses and indications. [1]Regulatory labelVictoza prescribing informationDailyMed label for liraglutide marketed as Victoza.
Identity + structure
A molecule, not a product name.
| Preferred name | Liraglutide | Ingredient |
|---|---|---|
| Pharmacologic class | GLP-1 receptor agonist | Profile record |
| Peptide structure | 31 amino acids | Profile record |
| Also indexed as | liraglutide · GLP-1 analog | Search aliases |
Mechanism + clinical pharmacology
Target, response, and disposition.
Activates GLP-1 receptors to increase glucose-dependent insulin secretion, decrease glucagon, reduce appetite, and delay gastric emptying. [1]Regulatory labelVictoza prescribing informationDailyMed label for liraglutide marketed as Victoza.
Evidence ledger
What the evidence says.
These are evidence statements, not individualized medical instructions. Product, dose, population, and study context remain attached to each source.
Study findings
What studies observed in defined populations, comparators, and time periods.
The mechanism section states liraglutide reduces glucagon secretion with glucose dependence, consistent with incretin physiology.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In sensitivity analyses of a matched cohort, GLP-1 receptor agonist exposure was associated with reduced risk of posterior subcapsular cataracts compared with alternative weight-loss medications.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The analysis evaluated short-term (1-, 3-, and 6-month) laryngeal symptom outcomes after GLP-1RA initiation, covering agents such as liraglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
For the prespecified primary composite time-to-event endpoint (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke), liraglutide reduced the hazard versus placebo with a hazard ratio below 1 and a 95% CI that did not include 1.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In a placebo-controlled cardiovascular outcomes trial, liraglutide lowered time-to-first 3-component MACE with an estimated hazard ratio below 1 and a 95% CI excluding 1.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Across randomized trials in adult cardiac-surgery patients, perioperative subcutaneous liraglutide showed no detectable difference in 30-day mortality versus control, with an imprecise pooled RR and wide CI.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Relative to liraglutide or dapagliflozin monotherapy, combined therapy showed greater metabolic benefit in the mouse T2DM model, specifically attenuating weight loss and improving glucose tolerance.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a rabbit model (normoglycaemic, non-obese; n=28), liraglutide was associated with a statistically significant reduction in progression of atherosclerosis, quantified by the IVUS change in percent atheroma volume relative to controls.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Across all liraglutide initiation timings, mean %TWL at 18 months exceeded control values, with statistical significance reported (P < 0.05).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this cohort, adherence assessed as proportion of days covered (PDC) averaged 48.7% for liraglutide (Saxenda) initiators.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a propensity score-matched cohort, GLP-1 receptor agonist use was associated with reduced 5-year incident dry eye syndrome compared with alternative weight-loss medications.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A meta-analysis pooling studies in ESRD estimated that liraglutide reduced body weight from baseline by -2.24 kg at 3 months, with wide uncertainty (95% CI includes both loss and gain) and no observed heterogeneity (I2= 0.0%).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In an in vitro HepG2 model of FFA-induced injury, liraglutide showed mitigation of steatosis-associated lipid accumulation and biochemical features of oxidative stress and iron overload.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide injection is used with diet and exercise to improve blood sugar control in adults and children age 10 years and older with type 2 diabetes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled therapeutic indication is adjunctive use with lifestyle measures to improve glycemic control in type 2 diabetes for adults and pediatric patients ≥10 years.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Ex vivo, islets from RIIβ-knockout mice had reduced insulin secretion when stimulated with liraglutide.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In an in vitro HUVEC assay, liraglutide elicited NO production comparable to tirzepatide when both were applied at equivalent molar concentrations, indicating similar endothelial NO output under those concentration-matched conditions.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a propensity score-matched cohort, GLP-1 receptor agonist exposure was associated with reduced 5-year incident ocular hypertension compared with alternative weight-loss medications.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this 56-week comparison, liraglutide produced greater mean weight loss than placebo, with a reported between-group difference and confidence interval using last-observation-carried-forward imputation.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Ex vivo, pancreatic islets from RIIβ-knockout mice had reduced insulin secretory responses when stimulated with liraglutide.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
This work evaluated liraglutide’s cardioprotective potential—both as monotherapy and combined with deferoxamine—in an in vivo rat model of doxorubicin-induced cardiotoxicity.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the murine T2DM model, combination treatment was associated with improved vascular structure (aortic architecture) and reduced endothelial apoptosis relative to monotherapies.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At 25 nmol/l, liraglutide potentiated glucose-stimulated insulin secretion in human donor islets specifically from the glucose-intolerance group (n=7; p=0.021), indicating metabolic-state dependence of the insulin secretory response.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The labeled indication includes chronic weight management (weight reduction and maintenance) when combined with reduced-calorie diet and increased physical activity, including adults and pediatric patients ≥12 years with body weight >60 kg and obesity.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In chow-fed mice, removing tanycyte GLP-1R signaling (GLP-1RTanycyteKD) eliminated liraglutide’s insulin-stimulating response, consistent with a need for tanycyte-mediated hypothalamic access.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the modeled broad-criterion population at full (100%) coverage, the projected annual medication-acquisition budget for liraglutide was S/142.95 billion.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In pooled randomized evidence for adult cardiac surgery, liraglutide did not change the composite endpoint of any postoperative complication relative to placebo or insulin-based usual care.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The adult weight-management clinical studies section states that, after 56 weeks, liraglutide injection resulted in statistically significant weight reduction compared with placebo in three randomized, double-blind, placebo-controlled trials.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In vitro assays reported that the nanomotor system increased insulin secretion relative to passive nanoparticles, with a stated 1.81-fold boost.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a propensity score-matched cohort, GLP-1 receptor agonist use was associated with reduced 5-year incident primary open-angle glaucoma relative to alternative weight-loss medications.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The gut bacterial community structure showed distinct treatment-associated changes that were largely reversible after a 7-day washout.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this mouse model, combination therapy reduced biochemical markers of myocardial injury (CK-MB and LDH) more than single-agent treatment.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this retrospective TriNetX cohort (2012–2024), liraglutide utilization showed a statistically significant upward monotonic trend by Mann-Kendall test (τ = .78; P = .002).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this narrative review, the authors state that the strongest direct randomized OSA-specific evidence among incretin therapies is concentrated in liraglutide (and tirzepatide).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
The pharmacodynamic description attributes weight lowering to decreased calorie intake and explicitly states no increase in 24-hour energy expenditure.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide injection is used to lower the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
As a GLP-1 receptor agonist, liraglutide can slow gastric motility, delaying gastric emptying.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In this mouse model, RIIβ knockout was associated with impaired glucose tolerance and reduced insulin secretory response to liraglutide.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The pharmacodynamic effect on body weight is attributed to reduced caloric intake rather than increased energy expenditure.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In the described mouse model, liraglutide produced statistically significant weight loss by Day 4 that continued through the dosing period and showed partial rebound after treatment ended.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A cardiovascular outcomes trial (LEADER) reported a lower hazard of first MACE with VICTOZA compared with placebo, quantified as a hazard ratio of 0.87 with a 95% CI of (0.78, 0.97).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Using human pancreatic islets, liraglutide at 25 nmol/l potentiated glucose-stimulated insulin secretion in the glucose intolerance group (n=7, p=0.021) while showing no effect in the normoglycaemic group (n=7).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a diabetic mouse model, an acute dose of the GLP-1R agonist liraglutide increased two intravital microvascular readouts: peri-islet vascular volume fraction and erythrocyte velocity.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
ASVs annotated to protein- and carbohydrate-fermenting genera (including Romboutsia, Faecalicatena, and Oscillibacter) were reduced during liraglutide exposure.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Relative to young control rats, the older acyclic control group exhibited increased body mass and adrenal remodeling: reduced adrenal weight/volume, cortical atrophy, increased collagen content, decreased STAR, and increased pAMPKα optical density, reported with p≤ 0.05.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Across active duty service members in the Military Health System cohort, liraglutide (Saxenda) showed lower persistence and adherence compared with tirzepatide (Zepbound) and semaglutide (Wegovy).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
According to the study’s summary, liraglutide produces rapid, diet-dependent, reversible microbiome shifts characterized by enrichment of lactic acid–producing taxa and suppression of fermentative taxa.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a propensity score-matched cohort analysis, GLP-1 receptor agonist exposure was associated with reduced use of dry eye-related medication compared with alternative weight-loss medications.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a type 2 diabetes mouse model, the nanomotor was reported to improve glucose tolerance, quantified as reducing OGTT-glucose area under the curve to 52.25% of the diabetic control value.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The abstract’s conclusion states that liraglutide reduced the rate of the primary composite event compared with placebo in a time-to-event framework.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In sensitivity analyses of a matched cohort, GLP-1 receptor agonist exposure was associated with reduced risk of the nuclear cataract subtype compared with alternative weight-loss medications.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Persistence at one year was 34.2% for liraglutide (Saxenda) initiators, and survival curves differed significantly across agents (log-rank P < .001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The labeled indication includes use alongside lifestyle measures (diet and exercise) to improve glycemic control in type 2 diabetes for adults and pediatric patients aged 10 years and older.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In this HepG2 in vitro injury model, FFA caused steatosis/oxidative-stress-related changes: more lipid accumulation and higher TG, MDA, and iron, with lower antioxidant measures (SOD activity and GSH) compared with control (all p<0.05).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this in-vitro model, liraglutide counter-regulated high-salt–induced increases in ACE1/AGTR1 and the high-salt–associated reduction in NHE3 phosphorylation.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a rabbit atherosclerosis model (normoglycaemic, non-obese; n=28), liraglutide treatment reduced plaque cathepsin activity measured by NIRF-OCT compared with controls.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
All-cause mortality hazard was lower in the liraglutide group compared with placebo in this randomized trial.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The abstract specifies the review’s scope as animal and human studies evaluating liraglutide’s effects on food intake and body weight.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
After 56 weeks, people on liraglutide lost more weight than placebo (difference -5.6 kg).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The abstract reports that in a type 2 diabetes mouse model the nanomotor system reduced insulin resistance, indicating improved insulin sensitivity in that animal model.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In sensitivity analyses of a matched cohort, GLP-1 receptor agonist exposure was associated with reduced risk of the cortical cataract subtype compared with alternative weight-loss medications.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this randomized comparison, liraglutide was associated with a lower hazard of death from cardiovascular causes versus placebo.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In this matched cohort analysis, GLP-1 receptor agonist exposure was associated with reduced risk of retinal haemorrhage or edema compared with alternative weight-loss medications.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Measurements in human donor islets indicate GLP-1R mRNA expression declines as HbA1c increases in type 2 diabetes islets (p=0.015 comparing normoglycaemic n=48 to type 2 diabetes n=10).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Clinical effectiveness in the main studies was assessed primarily by changes in glycosylated haemoglobin (HbA1c), measured at six months or one year, in adults and children with type 2 diabetes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In a propensity score-matched cohort study, exposure to GLP-1 receptor agonists (liraglutide or semaglutide) was associated with reduced 5-year incident cataract risk compared with alternative weight-loss medications.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a propensity score-matched analysis, GLP-1 receptor agonist use was associated with reduced 5-year incident age-related macular degeneration compared with alternative weight-loss medications.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this cross-sectional PCP survey, prior liraglutide prescribing experience was statistically associated with higher self-reported comfort managing patients’ weight after insurance loss of GLP-1-based drugs, with an adjusted odds ratio of 2.34 (95% CI 1.05-5.24).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Using claims-based target trial emulation and Cox proportional hazards models, GLP-1 receptor agonist initiation was not statistically significantly associated with increased NAION incidence compared with active comparators (SGLT-2i or DPP-4i), with an adjusted hazard ratio of 1.87 and a 95% CI spanning 1.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide lowers body weight by reducing calorie intake.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Its weight-lowering effect is attributed to reduced caloric intake rather than increased total daily energy expenditure.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In a rat doxorubicin cardiotoxicity model, liraglutide pretreatment significantly attenuated the set of measured cardiotoxicity-associated alterations (functional, biochemical, iron/oxidative stress, and ferroptosis-related readouts) reported for doxorubicin.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Using multivariable Cox proportional hazards, liraglutide (Saxenda) initiators had a higher modeled hazard of discontinuation than semaglutide (Wegovy) initiators (HR: 1.26; 95% CI: 1.01-1.16).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the rat drug-intervention experiment, liraglutide treatment was associated with a statistically significant reduction in tail-cuff systolic blood pressure compared with control.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The labeled indication is chronic weight management (weight reduction and maintenance) as an adjunct to lifestyle intervention in adults and eligible pediatric patients (≥12 years, >60 kg) with obesity.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
At 25 nmol/l, liraglutide potentiated glucose-stimulated insulin secretion in islets from glucose-intolerant donors (n=7; p=0.021).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Specific amplicon sequence variants (ASVs) annotated to Lactobacillus (gasseri, paragasseri, johnsonii) and Leptogranulimonas caecicola increased significantly under liraglutide dosing and decreased after washout.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In vitro cellular uptake in intestinal epithelial cells was higher for the self-propelled nanomotor than for passive nanoparticles, with a reported 4.17-fold increase in uptake efficiency.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The labeled indication is chronic weight management as an adjunct to reduced-calorie diet and increased physical activity for adults and eligible pediatric patients aged 12 years and older, including adults with overweight plus comorbidity and those with obesity.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Comparative evidence
How the studied intervention compared with another intervention, comparator, or threshold.
Comparability/manufacture: the source states Liraglutide STADA and Victoza share the same active substance, but Liraglutide STADA’s active substance is chemically synthesised versus biological origin in the reference product.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In an adult head-to-head monotherapy comparison versus glimepiride, liraglutide showed greater HbA1c lowering at the studied doses (1.2 mg and 1.8 mg) than glimepiride.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The study used random assignment and double-blinding to compare liraglutide versus placebo in a high cardiovascular-risk type 2 diabetes population.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide Stada is a hybrid medicine of Victoza (liraglutide), authorised in the EU since 30 June 2009.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The study’s primary kidney composite endpoint was defined using incident diagnosis codes capturing CKD stage 3-4 and kidney failure, including CKD stage 5 and kidney replacement therapy.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Solution-state diffusion behavior was reported as comparable for test products relative to the reference listed drug.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A target trial emulation using real-world data compared a Chinese herbal formula (MCLOW) versus liraglutide for weight control over a 12-month follow-up in individuals with BMI ≥ 25 kg/m².
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
This distinguishes manufacturing origin; it does not assert differences in clinical effects.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The study compared GLP-1RA recipients (liraglutide or semaglutide) with a 1:1 propensity score-matched cohort of users of alternative weight-loss medications.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The secondary composite endpoint extended the primary kidney composite by also including all-cause death.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The randomized-trial evidence summarized here uses placebo as the comparator for GLP-1RA interventions that include liraglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study directly compared a chemically synthesized liraglutide test product against a recombinant-origin reference listed drug in a head-to-head comparability design.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The combination regimen (liraglutide with deferoxamine) was reported as superior to each monotherapy across multiple endpoints of ventricular performance, iron homeostasis, antioxidant status, and histopathology in the doxorubicin injury model.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Among GLP-1 receptor agonists captured in follow-up time in this observational cohort, liraglutide had the highest contribution (72.9%) compared with semaglutide (13.4%), exenatide (7.3%), dulaglutide (5.1%) and lixisenatide (1.3%).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this comparative effectiveness analysis, liraglutide did not differ from dulaglutide, exenatide, or semaglutide on the primary kidney composite endpoint.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a pediatric/adolescent placebo-controlled study (n=134; age 10 years and above), liraglutide reduced HbA1c while placebo was associated with an HbA1c increase.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The comparator group for the disproportionality analysis was other glucose-lowering medications, and outcomes assessed included depressed mood and suicidal thoughts for GLP-1RAs such as liraglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this network meta-analysis of randomized controlled trials, liraglutide treatment was associated with reduced lean body mass; the pooled estimate was a mean difference of -1.54 kg with a 95% confidence interval from -2.55 to -0.52.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Mechanism
Source-backed statements about targets, pathways, and biological response.
In the diabetic mouse model, inhibiting nitric oxide synthase with L-NAME eliminated the acute microvascular responses observed with liraglutide, consistent with NO-dependent mediation.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
An in vitro reporter (luciferase) assay for AVP was created to evaluate how phosphorylation of synaptic proteins influences AVP secretion.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Physiologic effect described: liraglutide increases food-stimulated pancreatic insulin release and is stated to help control blood glucose levels.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The study evaluates liraglutide in an in vitro diabetic-like environment using NHDFs and NHEKs to assess oxidative-stress and wound-repair-related endpoints.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Mechanistically, liraglutide is a GLP-1 receptor agonist that triggers Gs-coupled adenylyl cyclase signaling upon receptor activation.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
To probe liraglutide mechanisms, the methods included tanycyte-specific GLP-1R knockdown mice (GLP-1RTanycyteKD) and botulinum toxin B-expressing (iBot) mice, intended to distinguish central vs peripheral pathways.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
After statistical adjustment for weight, 85 % of observed proteomic effects remained, which is interpreted as largely weight-independent actions.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
As an incretin mimetic, liraglutide acts like gut incretins to enhance glucose-dependent pancreatic insulin secretion, supporting glycaemic control.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
As a GLP-1 receptor agonist, liraglutide activates GLP-1R signaling that increases intracellular cAMP in pancreatic beta cells, which promotes insulin secretion under hyperglycemic conditions.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The study concludes that GLP-1 receptor activation produces a rapid increase in islet microvascular flow that depends on nitric oxide signaling, and that this response is specific to diabetic conditions.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide is a long-acting GLP-1 receptor agonist.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a cell-based functional assay (HTRF), liraglutide acted as a GLP-1 receptor agonist, inducing cAMP accumulation with a reported EC50 of 0.0093 nM after 20 minutes.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide is categorized as a glucagon-like peptide-1 receptor agonist (GLP-1 RA), a drug class defined by agonism at the GLP-1 receptor.
2 cited sources · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records. 2 publication group(s) lack a resolved study identity.
Liraglutide works by activating the GLP-1 receptor.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Delayed gastric emptying may affect absorption of oral drugs; this statement alone does not quantify the magnitude or clinical impact.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In an in vitro HepG2 injury model, liraglutide modulated ferroptosis-associated markers versus FFA alone: it decreased oxidative damage (MDA) and iron content, reduced the iron transporter marker TFR1, and increased NRF2 and GPX4, consistent with partial attenuation of ferroptosis pathways (all p<0.05).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The source characterizes liraglutide as an oligomer-forming peptide with oligomers that lack intrinsic stability under agitation stress, which is relevant to interpreting aggregation behavior under interfacial/agitation conditions.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1RAs are described as having cardiometabolic effects not solely explained by weight loss; however, the systemic proteomic mechanisms are stated to be incompletely defined.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide increases cAMP and triggers insulin release when blood glucose is high.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
An orthogonal framework combining spectroscopic, biophysical, NMR-based, and in vitro functional assays was applied to characterize secondary structure, supramolecular assembly, aggregation propensity, conformational fingerprints, and biological activity.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The aim was to test whether heterogeneity in patient responses could reflect metabolic state-dependent shifts in liraglutide’s mode of action across stages of metabolic dysfunction.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
This work is described as profiling short-term proteomic changes induced by liraglutide and comparing those changes with published semaglutide proteomic signatures.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The study quantified GLP-1R mRNA expression in 112 donor islet preparations and stratified results by HbA1c.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The results indicate a progressive decline in GLP-1R mRNA expression with increasing HbA1c when comparing normoglycaemic (n=48) to type 2 diabetes (n=10) donor islets (p=0.015).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Glucagon-like peptide-1 receptor agonists are described as reducing glucose in a glucose-dependent manner (only when glucose is elevated).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this in vitro HepG2 model, the reported improvements with liraglutide were associated with altered expression of ferroptosis-associated genes, supporting a mechanistic connection to ferroptosis regulation.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
This work investigated liraglutide in an in vitro MASLD-related setting, focusing on whether it can attenuate ferroptosis (an iron-dependent regulated cell-death pathway).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide activates the GLP-1 receptor.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide lowers blood glucose partly by slowing gastric emptying, affecting the rate of nutrient delivery and glucose appearance.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Mechanistically, liraglutide is reported to activate the GLP-1 receptor (Gs-coupled) on pancreatic beta cells, raising intracellular cAMP and promoting insulin secretion under hyperglycemic conditions.
4 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
5 cited passages across 4 source records.
As a GLP-1 receptor agonist, liraglutide triggers GLP-1 receptor signaling via Gs-dependent adenylyl cyclase activation.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In this analysis, liraglutide (a GLP-1RA) was evaluated by aggregating injection-site events with skin-related adverse events into a single adjusted category for cross-agent comparison.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
With advanced metabolic disease (27-week high-fat diet) in mice, liraglutide preserved ex vivo islet responsiveness but did not enhance insulin in vivo; the reported glucose-lowering relied on insulin-independent mechanisms, including suppression of hepatic gluconeogenesis and increased peripheral glucose uptake.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide activates the GLP-1 receptor and is characterized as long-acting.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
NMR evidence in the source indicates a specific peptide–surfactant interaction for liraglutide with PS80, whereas analogous interaction was not observed with PX188.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Molecular pathway readouts were assessed using protein (Western blot) and gene-expression (qPCR) methods.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the HepG2 in vitro model, FFA treatment shifted ferroptosis-associated gene/protein markers versus control by increasing TFR1 and decreasing SLC7A11, NRF2, and GPX4 (all p<0.05).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Pharmacokinetics
How the studied compound is absorbed, distributed, metabolized, and cleared.
The pharmacokinetics section states time to maximum concentration (Tmax) occurs at 8 to 12 hours after subcutaneous administration.
5 cited sources · 4 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
6 cited passages across 5 source records.
After subcutaneous administration, liraglutide is cleared with an approximate terminal half-life of 13 hours.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide (Lira) in the nanomotor system was encapsulated in sodium alginate-based hydrogel microspheres (SAM) as a gastrointestinal protection strategy against gastric-acid-induced degradation.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The absorption phase after subcutaneous administration yields a Tmax of 11 hours.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide is reported to persist in plasma with a 13-hour half-life after subcutaneous administration, supporting once-daily dosing.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Absorption kinetics: the time to maximum concentration (Tmax) after subcutaneous dosing is 8–12 hours.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The time to maximum concentration (Tmax) after subcutaneous injection is 8-12 hours for liraglutide.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The pharmacokinetics section reports a time to maximum concentration (Tmax) of 8 to 12 hours after subcutaneous administration.
2 cited sources · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 2 source records.
Liraglutide absorption after subcutaneous injection results in peak plasma concentrations (Tmax) at 8–12 hours.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
The absorption phase after subcutaneous injection is slow, with peak liraglutide concentrations occurring 8-12 hours after dosing.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Time to peak concentration (Tmax) after subcutaneous administration is reported as 11 hours post-dose.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The time to peak concentration (Tmax) after subcutaneous dosing is reported as 11 hours.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The source states that liraglutide’s stability against enzymatic degradation is associated with a plasma half-life of 13 hours after subcutaneous dosing.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Animal lactation data report transfer of unchanged liraglutide into rat milk at concentrations approximately half of maternal plasma concentrations.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Within the GLP-1 receptor agonist exposure group of this observational cohort, liraglutide represented 72.9% of accumulated follow-up time, indicating it was the predominant GLP-1 receptor agonist contributing to exposure time.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Compared with native GLP-1, liraglutide persists longer in plasma; the label reports a 13-hour half-life after subcutaneous administration.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Safety findings
Observed or labeled risks, adverse effects, and safety signals.
Routine calcitonin blood tests or thyroid ultrasound may not reliably detect MTC early in people treated with liraglutide injection.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This warning is specifically about combination therapy in adults and does not provide a numeric risk estimate here.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The boxed warning states a rodent carcinogenicity finding (dose- and duration-dependent thyroid C-cell tumors at clinically relevant exposures) and explicitly notes that human relevance is unknown.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Immunogenicity testing in a subset of adults treated with VICTOZA in five double-blind trials found anti-liraglutide antibodies in 102 out of 1,104 tested patients (9%).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Across VICTOZA clinical trials, severe gastrointestinal adverse reactions occurred at higher percentages in liraglutide dose groups (1.2 mg and 1.8 mg) compared with placebo.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Nonclinical findings report dose- and treatment-duration-dependent thyroid C-cell tumors in rodent studies at clinically relevant exposures, while human relevance and whether VICTOZA causes thyroid C-cell tumors (including MTC) in humans is not known.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The statement describes an observed safety risk but does not quantify incidence in this section.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The source lists gastrointestinal adverse effects as the most common, with frequency described as possibly affecting more than 1 in 10 people.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The pregnancy section provides a risk statement derived from animal reproduction studies and a conditional-use recommendation during pregnancy based on benefit–risk judgment.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Rodent studies reported thyroid C-cell tumor findings that increased with higher dose and longer exposure to liraglutide; translation of this risk to humans (including MTC) is not established.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Nonclinical toxicology described in the warning indicates rodent thyroid C-cell tumor findings that vary with dose and treatment duration at clinically relevant exposures.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Despite rodent thyroid C-cell tumor findings, the human relevance is stated as not determined, so a causal risk in humans is described as unknown.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Pregnancy labeling states fetal risk concern based on animal studies; therapy is advised only when benefit outweighs risk, and intentional weight loss during pregnancy may be harmful.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not share a liraglutide injection pen with anyone else, even if you change the needle, because it can spread blood-borne infections.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The boxed warning reports rodent thyroid C-cell tumor findings (dose- and duration-dependent at clinically relevant exposures in rats and mice) and states that the human relevance is not determined.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The clinical trials experience section summarizes LEADER as assessing cardiovascular safety in 9,340 patients and reports that no increased risk for major adverse cardiovascular events (MACE) was observed for liraglutide 1.8 mg vs placebo, with a median follow-up of 3.5 years.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Rodent toxicology findings show thyroid C-cell tumorigenesis that depends on dose and duration at clinically relevant exposures; human relevance has not been determined.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not share a Victoza pen, even with a new needle, because it can spread blood-borne infections.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Contraindications
Circumstances in which a specific product label says it should not be used.
Because of thyroid C-cell tumor concerns, liraglutide injection is contraindicated for patients with medullary thyroid carcinoma history (personal or familial) and for those with MEN 2.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
The contraindications include personal/family history of medullary thyroid carcinoma and presence of MEN 2, reflecting thyroid C-cell tumor risk considerations.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Because of thyroid C-cell tumor risk considerations, SAXENDA use is contraindicated in patients with MTC history (personal/family) or MEN 2.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Contraindications include personal/family history of medullary thyroid carcinoma and presence of MEN 2, due to thyroid C-cell tumor risk considerations.
4 cited sources · 3 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
4 cited passages across 4 source records.
Do not use liraglutide injection if you or your family have had MTC, or if you have MEN 2.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide injection is contraindicated in individuals at elevated baseline risk for medullary thyroid carcinoma, including those with MEN 2.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Because of thyroid C-cell tumor risk warnings, the label lists personal/family MTC and MEN 2 as contraindications to SAXENDA use.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The label lists MTC (personal/family history) and MEN 2 as contraindications to liraglutide use.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
The contraindications include personal/family history of medullary thyroid carcinoma and presence of Multiple Endocrine Neoplasia syndrome type 2.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Because of thyroid C-cell tumor risk concerns, liraglutide is contraindicated in individuals with personal/family history of MTC or MEN 2.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide use is contraindicated in individuals with medullary thyroid carcinoma history (personal/family) or multiple endocrine neoplasia syndrome type 2 due to thyroid C-cell tumor risk concerns.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Do not use liraglutide in people with a personal or family history of MTC or with MEN 2.
2 cited sources · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
The product is contraindicated in populations at elevated baseline risk for medullary thyroid carcinoma, specifically those with personal/family history of MTC or MEN 2.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The contraindications section lists MTC history (personal or family) and MEN 2 as contraindications to liraglutide use.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
The product labeling lists MTC history (personal or familial) and MEN 2 as contraindications to VICTOZA use.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide injection has a labeled contraindication for individuals with personal/family history of MTC or with MEN 2 due to thyroid C-cell tumor risk concerns.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Because of thyroid C-cell tumor concerns, VICTOZA (liraglutide) is contraindicated in patients with personal/family MTC or MEN 2.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The label lists MTC history (personal/family) and MEN 2 as contraindications to liraglutide (VICTOZA).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Contraindications include MTC (personal/family history), MEN 2, and prior serious hypersensitivity to liraglutide or excipients (including reported anaphylaxis/angioedema).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use SAXENDA if you or your family have had MTC, or if you have MEN 2.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Interactions
Source-backed product and drug interaction statements.
Because the product already contains liraglutide, combining it with other liraglutide-containing therapies is not recommended.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The label discourages combination therapy with other liraglutide-containing products or other GLP-1 receptor agonists, implying a recommended avoidance of such coadministration.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
By delaying gastric emptying, liraglutide injection can alter the timing and potentially the absorption of co-administered oral drugs.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use Liraglutide Injection together with other products that contain liraglutide.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Because SAXENDA contains liraglutide (a GLP-1 receptor agonist), the label advises against combining it with other liraglutide-containing therapies or other GLP-1 receptor agonists.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Concomitant therapy with other GLP-1 receptor agonists (including other liraglutide-containing products) is not recommended, likely due to overlapping pharmacology and safety considerations.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeling advises against combined use with other liraglutide-containing medicines or any other GLP-1 receptor agonist, implying potential duplication of GLP-1RA therapy.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This limitation of use is a labeling recommendation (not a quantified interaction study outcome).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Co-administration guidance: liraglutide and insulin should not be combined in the same injection; they must be given as separate injections.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Concomitant use with sulphonylurea or insulin may warrant dose reduction of the sulphonylurea/insulin to mitigate hypoglycaemia risk.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide’s insulinotropic action is described as glucose-dependent, increasing insulin release during hyperglycemia.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use Liraglutide Injection together with other medicines that also contain liraglutide.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Because liraglutide injection contains liraglutide, concurrent use with other liraglutide-containing products or any GLP-1 receptor agonist is not recommended.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Because concomitant sulphonylurea or insulin therapy may increase hypoglycaemia risk when adding liraglutide, dose reduction of the co-administered agent is advised for consideration.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Using liraglutide with a sulfonylurea or insulin can increase the risk of hypoglycemia, including severe hypoglycemia.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not combine liraglutide injection with other liraglutide products or other GLP-1 receptor agonists.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Regulatory status
Product-, indication-, and jurisdiction-specific regulatory records.
The labeling recommends avoiding coadministration with other liraglutide-containing products (duplicate GLP-1 RA active ingredient exposure).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled cardiovascular indication specifies risk reduction for a 3-component MACE composite in adults with T2DM and established CVD.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The indication specifies combination with a reduced calorie diet and increased physical activity and defines eligible adult and pediatric groups by age, weight, obesity/overweight status, and comorbidity presence.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Regulatory status: EU-wide marketing authorisation was granted for Victoza on 30 June 2009.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
The approved cardiovascular indication for liraglutide (VICTOZA) is risk reduction of MACE (cardiovascular death, non-fatal MI, non-fatal stroke) in adults with type 2 diabetes and established CVD.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
On 21 May 2026, the CHMP recommended granting marketing authorisation for Liraglutide Stada.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled cardiovascular indication is risk reduction for MACE (cardiovascular death, non-fatal MI, non-fatal stroke) in adults with T2DM and established cardiovascular disease.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide Injection is used with diet and exercise to improve blood sugar control in adults and children age 10 years and older with type 2 diabetes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
EMA concluded Saxenda’s benefits outweigh its risks and it can be authorised in the EU.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled cardiovascular-risk-reduction indication is for adults with type 2 diabetes mellitus and established cardiovascular disease, targeting major adverse cardiovascular events (CV death, non-fatal MI, non-fatal stroke).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The approved indication described is chronic weight management (with reduced calorie diet and increased physical activity) for adults and for pediatric patients aged 12 years and older meeting the label’s weight/obesity criteria, plus adults with overweight and at least one weight-related comorbidity.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The approved indication includes using liraglutide as adjunct therapy to diet and exercise for glycemic control in type 2 diabetes in patients aged 10 years and older.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Administration
Product-specific route, timing, formulation, and use instructions—not universal dosing advice.
The labeled route and schedule are subcutaneous administration once daily; dosing is independent of meal timing.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The dosing instructions specify subcutaneous administration once daily without regard to meal timing.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Inject liraglutide under the skin once daily, any time of day, with or without meals, in the abdomen, thigh, or upper arm.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The product is formulated as a 6 mg/ml injectable solution in pre-filled pens for once-daily subcutaneous administration at approved injection sites (abdomen, thigh, upper arm).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Administration timing is flexible: once-daily subcutaneous dosing independent of food intake.
4 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
4 cited passages across 4 source records.
Inject SAXENDA under the skin once daily (any time, with or without meals) in the abdomen, thigh, or upper arm.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Inject liraglutide under the skin once daily, any time of day, with or without meals.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Administration is subcutaneous once daily without regard to meals, using approved injection sites (abdomen, thigh, upper arm).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The administration instructions specify a subcutaneous route, once-daily frequency, and no meal-timing requirement.
3 cited sources · 3 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 3 source records.
The instructions specify physical separation of liraglutide and insulin administration; mixing is prohibited.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Administration is described as once-daily subcutaneous injection via a pre-filled pen, with permitted sites including thigh, upper arm, or abdomen.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled administration route is subcutaneous, with once-daily dosing that is not tied to meal timing.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The source gives a discontinuation criterion based on percent loss of initial body weight after 12 weeks on the maximum or maximum tolerated dose, with thresholds differing by age group.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
After an interruption of >3 days, the label instructs restarting liraglutide at 0.6 mg once daily (reinitiation step) to reduce gastrointestinal adverse reactions.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
If you miss liraglutide for more than 3 days, restart at 0.6 mg daily and re-titrate.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The administration instructions specify subcutaneous once-daily dosing, not meal-dependent, with injection sites including abdomen, thigh, or upper arm.
6 cited sources · 4 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
6 cited passages across 6 source records.
Administration instructions specify subcutaneous dosing once daily and that dosing time does not need to be coordinated with meals.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Victoza is injected under the skin once daily (abdomen, thigh, or upper arm), independent of meals, preferably at the same time each day.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Administration is subcutaneous, once daily, and is not dependent on meal timing.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
If you miss liraglutide for more than 3 days, restart at 0.6 mg once daily.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
If using insulin too, inject liraglutide separately and never mix them; they can be in the same general area but not right next to each other.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This addresses labeled injection sites and states no dose adjustment is needed for site/timing changes; it does not discuss differences in exposure in this section.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled route/frequency is subcutaneous once-daily dosing independent of meal timing; approved injection sites include abdomen, thigh, and upper arm.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide (as Saxenda) is administered subcutaneously once daily via a pre-filled pen; injection sites include thigh, upper arm, or abdomen.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
The labeled route and frequency are subcutaneous administration once daily, independent of meal timing.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Approved subcutaneous injection sites include abdomen, thigh, and upper arm.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Inject liraglutide under the skin once daily (any time of day), in the abdomen, thigh, or upper arm; meal timing does not matter.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Dose records
Product- and indication-specific dose statements preserved separately to prevent unsafe generalization.
The dosage form is a subcutaneous solution (6 mg/mL) in a 3 mL prefilled pen with selectable delivered doses from 0.6 mg to 3 mg.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Adult titration begins at 0.6 mg SC once daily for one week to improve gastrointestinal tolerability; this starting dose is explicitly stated as ineffective for adult glycemic control.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Adult titration step: escalate from 0.6 mg QD to 1.2 mg QD after one week at the starting dose.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
A stepwise titration is specified: 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4), then 3 mg (week 5+).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Adult titration begins with 0.6 mg once daily for 1 week, followed by escalation to 1.2 mg once daily.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Start at 0.6 mg daily for 1 week, then increase weekly to 3 mg daily by week 5.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Adult dosing is initiated at 0.6 mg subcutaneously once daily for one week as the recommended starting regimen.
3 cited sources · 3 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 3 source records.
The labeled dosage form is a prefilled pen containing liraglutide 6 mg/mL (3 mL total volume) with selectable delivered doses from 0.6 mg to 3 mg.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For adults requiring additional glycemic control, the dose escalation step from 1.2 mg to 1.8 mg occurs after a minimum of one week at 1.2 mg once daily.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The label states 0.6 mg is for initial titration and is not effective for glycemic control in adults; escalation is intended to reduce gastrointestinal adverse reactions.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The adult titration schedule specifies escalation from 0.6 mg QD after one week to 1.2 mg QD via subcutaneous injection.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Adults: target dose is 3 mg daily; stop SAXENDA if 3 mg is not tolerated.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The pediatric titration schedule mirrors adult escalation steps, beginning at 0.6 mg daily, then optionally 1.2 mg daily after ≥1 week, and optionally 1.8 mg daily after ≥1 week at 1.2 mg when additional glycemic control is required.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Adult maintenance dosing is 3 mg once daily, with lower doses intended solely for the titration phase.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 2 source records.
The missed-dose guidance states that when the dosing gap exceeds 3 days, treatment should be reinitiated at 0.6 mg once daily.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The maintenance dose for adults is 3 mg once daily; smaller doses are intended only for dose-escalation/titration.
3 cited sources · 3 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 3 source records.
Adult titration is weekly: initiate 0.6 mg SC daily for 1 week, escalate to 1.2 mg SC daily, and (if needed) to 1.8 mg SC daily after ≥1 week at 1.2 mg; 1.8 mg is the maximum recommended adult dose.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Adult initiation uses subcutaneous liraglutide 0.6 mg once daily for one week as the recommended starting dosage.
4 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
4 cited passages across 4 source records.
The dosing schedule described is titration from 0.6 mg to 1.2 mg after at least one week, with an optional escalation to 1.8 mg one week later for some patients.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Adult titration may be increased up to a labeled maximum of 1.8 mg subcutaneously once daily.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Adult initiation dosing: 0.6 mg subcutaneously once daily for one week as the starting dose.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Adult dosing guidance specifies a 3 mg daily maintenance dose, with lower doses reserved for titration rather than maintenance therapy.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The adult maintenance dose is 3 mg once daily; sub-3 mg doses are intended only for the titration phase.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The label links gradual increases to reducing gastrointestinal adverse reactions; it does not specify a single required titration endpoint besides the 1.8 mg maximum.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The dosing section provides a fixed weekly titration schedule with specific daily doses across Weeks 1 through 5 and onward.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In pediatric type 2 diabetes (≥10 years), labeled maximum maintenance dose is 1.8 mg SC once daily.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This titration schedule is intended to guide dosing; separate stop rules and maintenance alternatives appear elsewhere in the same section.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The marketed dosage form is a 6 mg/mL liraglutide solution in a single-patient pen with selectable doses of 0.6 mg, 1.2 mg, and 1.8 mg.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Adult up-titration permits escalation from 1.2 mg QD to a maximum of 1.8 mg QD after ≥1 week at the 1.2 mg dose when additional glycemic control is required.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Adult titration per labeling begins at 0.6 mg daily for one week, then escalates to 1.2 mg daily; an additional step to 1.8 mg daily may occur after ≥1 week at 1.2 mg if further glycemic control is required.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Pediatric (≥10 years) titration begins at 0.6 mg SC daily with stepwise 0.6 mg increases after ≥1 week at each dose, to a maximum of 1.8 mg SC daily, when additional glycemic control is required.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Missed-dose guidance: after >3 days since the last dose, reinitiate at 0.6 mg once daily to mitigate gastrointestinal adverse reactions on reinitiation.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled titration schedule increases the daily subcutaneous dose stepwise each week from 0.6 mg to a 3 mg maintenance dose beginning week 5.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The dosing section provides a weekly titration (0.6 mg → 1.2 mg → 1.8 mg → 2.4 mg → 3 mg daily) intended to reduce gastrointestinal adverse reactions, with 3 mg daily stated as the recommended adult dose.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The dosing schedule includes a titration period lasting 4 weeks.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 1 source record.
Studied populations
Who was represented in a study, label, or registry record.
Liraglutide STADA is intended to treat insufficiently controlled type 2 diabetes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Victoza is used with diet and exercise for adults and children aged 10 years and older with type 2 diabetes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide STADA is indicated for adults, adolescents, and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The label recommends no dose adjustment in renal impairment (with referenced clinical pharmacology).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Identity
Ingredient, molecule, and product identity statements.
The methods describe liraglutide as an agonist of the glucagon-like peptide-1 receptor (GLP-1R), i.e., a compound used to activate GLP-1R signaling.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this meta-analysis, liraglutide is listed as a GLP-1 receptor agonist (GLP-1RA) studied in randomized trials enrolling people with Parkinson’s disease.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Exposure to GLP-1 receptor agonist therapy was operationalized via prescription records, and liraglutide was one of the GLP-1 agents included in that exposure definition.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The text places liraglutide within the GLP-1 RA drug class, i.e., a glucagon-like peptide-1 receptor agonist evaluated in this cohort analysis.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The methods explicitly list liraglutide among the GLP-1 receptor agonists used as interventions.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
This paper explicitly defines liraglutide as a GLP-1 analogue in its mouse/islet experiments; it does not describe other properties (e.g., human indications) in these sections.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide is classified as a GLP-1 receptor agonist, a drug class used among obesity medications.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide is described as a GLP-1 analog pharmacologically functioning as a GLP-1 receptor agonist.
3 cited sources · 3 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 3 source records.
Liraglutide is a lipidated peptide that acts as an agonist at the GLP-1 receptor.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The medicinal product Victoza uses liraglutide as its active ingredient.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide was one of the GLP-1 receptor agonist (GLP-1 RA) agents specified as the exposure category in the analysis.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide in this product is described as an analog of human GLP-1, and it functions pharmacologically as a GLP-1 receptor agonist.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide is classified as an analogue of glucagon-like peptide 1 (GLP-1).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide acts as an agonist at the GLP-1 receptor.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide injection contains liraglutide, a GLP-1 analog that acts as a GLP-1 receptor agonist.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
ChEMBL classifies liraglutide’s molecule type as a protein.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide belongs to the drug class of glucagon-like peptide-1 receptor agonists (GLP-1 RA), meaning it acts via the GLP-1 receptor.
2 cited sources · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records. 2 publication group(s) lack a resolved study identity.
Liraglutide in this product is described as an analog of human GLP-1 that functions pharmacologically as a GLP-1 receptor agonist.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The product contains liraglutide, a peptide engineered as a GLP-1 analog that pharmacologically functions by agonizing the GLP-1 receptor.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Liraglutide is structurally based on human GLP-1 and pharmacologically functions by agonism of the GLP-1 receptor.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide is identified as the active substance in the medicine Saxenda.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide is categorized as a GLP-1 receptor agonist in comparative evaluations of pharmacotherapies for overweight/obesity.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The abstract refers to liraglutide as a glucagon-like peptide-1 (GLP-1) analog.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide in this product is described as an analog of human glucagon-like peptide-1 (GLP-1) with GLP-1 receptor agonist activity.
2 cited sources · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Structurally, liraglutide is an acylated analog that closely matches endogenous GLP-1(7-37) (97% sequence homology) and functions as a GLP-1 receptor agonist.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide (ATC A10BJ02) is identified here as a glucagon-like peptide-1 analogue and is the active substance in Liraglutide STADA.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In this review of pharmacotherapy for obstructive sleep apnoea, liraglutide is categorized within the drug class of GLP-1 receptor agonists.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide is categorized as a glucagon-like peptide-1 receptor agonist (GLP-1 RA) among anti-obesity medications.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue, i.e., a peptide analog used to stimulate GLP-1–linked signaling pathways.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide is described as an analogue of glucagon-like peptide 1 (GLP-1).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide is categorized as a long-acting agonist of the GLP-1 receptor (GLP-1R).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
ChEMBL molecular properties list liraglutide with formula C172H265N43O51.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide is a GLP-1 analog; its amino-acid sequence is reported to be 97% homologous to human glucagon-like peptide-1 (GLP-1).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
As part of its narrative review methods, the authors used "liraglutide" as a search descriptor and included publications spanning 2014 to 2025.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The cohort included initiators of liraglutide, with the brand name Saxenda, as one of the GLP-1RA therapies examined.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide in SAXENDA is described as an analog of human GLP-1 and functions pharmacologically as a GLP-1 receptor agonist.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide in VICTOZA is a glucagon-like peptide-1 (GLP-1) analog designed to activate the GLP-1 receptor (i.e., a GLP-1 receptor agonist).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide was included among the main GLP-1 receptor agonist interventions evaluated in the included studies of this systematic review/meta-analysis.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide is classified as a GLP-1R agonist and is used in the management of type 2 diabetes and obesity.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
ChEMBL molecular properties list liraglutide with a molecular weight of 3751.26.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide Injection comes as a clear, colorless solution (18 mg/3 mL; 6 mg/mL) in a prefilled single-patient pen that can deliver 0.6 mg, 1.2 mg, or 1.8 mg.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The product is supplied as a prefilled pen containing an 18 mg per 3 mL (6 mg/mL) solution, designed for single-patient use and capable of delivering 0.6 mg, 1.2 mg, or 1.8 mg dose settings.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Liraglutide is categorized as a glucagon-like peptide-1 receptor agonist (GLP-1 RA), a drug class acting via the GLP-1 receptor.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide was one of the GLP-1–based receptor agonists included for comparative evaluation of efficacy and safety in overweight/obesity pharmacotherapy.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Additional research & classification gaps
35 archived statements are kept separate from drug-effect findings. Media studies, economic models, methods, and records with unresolved scope are not used as medical-effect evidence.
Inspect contextual research (35)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Responder rates for categorical weight loss thresholds were lower for liraglutide than for MCLOW in this dataset: ≥ 5% (23.65% vs. 68.15%) and ≥ 10% (7.05% vs. 32.59%), with both comparisons reported as statistically significant.
Research context only—not evidence of a treatment effect.
- pubmed-42500463
and had a higher proportion achieved weight reductions of ≥ 5% and ≥ 10% (68.15% vs. 23.65%,p< 0.001 and 32.59% vs. 7.05%, p-value < 0.001, respectively).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Using a semaglutide-derived proteomic classifier, the analysis discriminated liraglutide from placebo with the reported AUC, sensitivity, and specificity.
Research context only—not evidence of a treatment effect.
- Proteomic effects of short-term liraglutide vs. placebo in a blinded crossover RCT: Implications for efficacy, safety, and comparison with semaglutide.
A semaglutide-based classifier distinguished liraglutide from placebo (AUC = 0.82; sensitivity 0.89; specificity 0.60).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The methods state that findings were benchmarked to an existing semaglutide proteomic signature consisting of 30 proteins from STEP 1/2.
Research context only—not evidence of a treatment effect.
- Proteomic effects of short-term liraglutide vs. placebo in a blinded crossover RCT: Implications for efficacy, safety, and comparison with semaglutide.
Results were benchmarked against the 30-protein semaglutide STEP 1/2 signature.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The review’s included studies used placebo or SGLT-2 inhibitors as comparators for GLP-1RA therapy (a group that included liraglutide).
Research context only—not evidence of a treatment effect.
- Assessing the risk of diabetic retinopathy progression with GLP-1 receptor agonists: a systematic review and meta-analysis.
The primary GLP-1RAs analyzed were albiglutide, liraglutide, semaglutide, exenatide, and dulaglutide, compared to either placebo or SGLT-2 inhibitors.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a nationwide analysis of GLP-1 receptor agonist use and spending in Croatia, semaglutide ranked first for both utilization and expenditure, with dulaglutide and liraglutide ranking next.
Research context only—not evidence of a treatment effect.
- Trends in glucagon-like peptide-1 receptor agonist utilization and expenditure in Croatia.
Semaglutide emerged as the dominant agent according to both utilization and cost, followed by dulaglutide and liraglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Multivariate model interpretation using loading and contribution line plots highlighted which spectral regions/features drove the major variance in the dataset.
Research context only—not evidence of a treatment effect.
- pubmed-42330703
The application of principal component analysis (PCA) enabled the identification of clustering patterns and classification of samples under different stress conditions, while the analysis of loading and contribution line plots allowed recognition of the main spectral features contributing most to the variance.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the network meta-analysis, the liraglutide QD arm showed a statistically significant reduction in body weight compared with control, quantified as a negative standardized mean difference with a 95% confidence interval excluding zero.
Research context only—not evidence of a treatment effect.
- Glucagon-like peptide-1 receptor agonists for weight management in mental illness: a network meta-analysis.
S-LIR(QD) and S-SEM(QW) were significantly associated with reduced body weight compared with control, with standardized mean differences (95% confidence intervals) of -0.945 ( - 1.784 to -0.106) and -2.101 ( - 2.978 to -1.224), respectively.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In this proteomic analysis, liraglutide is reported to significantly modulate 124 proteins, with 57 meeting FDR < 0.05.
Research context only—not evidence of a treatment effect.
- Proteomic effects of short-term liraglutide vs. placebo in a blinded crossover RCT: Implications for efficacy, safety, and comparison with semaglutide.
Liraglutide significantly modulated 124 proteins (57 FDR < 0.05)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the modeled 100% coverage scenario using the broad candidate criterion, the estimated annual budget impact for liraglutide was S/142.95 billion.
Research context only—not evidence of a treatment effect.
- pubmed-42565180
At 100% coverage, broad-criterion annual budgets were S/142.95 billion for liraglutide
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The results list specific upregulated proteins under liraglutide, including pancreatic enzymes PNLIP, CTRB1/2, and PRSS2.
Research context only—not evidence of a treatment effect.
- Proteomic effects of short-term liraglutide vs. placebo in a blinded crossover RCT: Implications for efficacy, safety, and comparison with semaglutide.
Upregulated proteins included pancreatic enzymes (PNLIP, CTRB1/2, PRSS2)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Liraglutide is used therapeutically for weight-loss induction.
Research context only—not evidence of a treatment effect.
- Effects of liraglutide on gut bacterial community dynamics.
is used to induce weight loss.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study conclusion states that, in real-world data, semaglutide initiators had lower incidence of diabetes than liraglutide initiators.
Research context only—not evidence of a treatment effect.
- Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data.
In this real-world study, semaglutide users had lower risk of incident diabetes compared with liraglutide users.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Using Cox regression with propensity-score adjustment, diabetes incidence was lower for semaglutide initiators than for liraglutide initiators over a mean follow-up of 1 year (HR: 0.88; 95% CI: 0.78, 0.99).
Research context only—not evidence of a treatment effect.
- Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data.
Over 1-year mean follow-up, we observed 1104 diabetes events and 57 CVD events. After regression adjustment, semaglutide users had 12% lower risk of diabetes (hazard ratio [HR]: 0.88; 95% CI: 0.78, 0.99).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a bacterial recombinant expression setup using a SUMO–liraglutide-derived peptide fusion, engineered 3'-UTR hairpins (placed downstream of the coding sequence) were associated with an ~3-fold higher cellular fusion-protein content relative to a control construct, with p < 0.001 (n = 6).
Research context only—not evidence of a treatment effect.
- Engineering 3'-UTR hairpin structures to modulate mRNA stability and recombinant protein production in Escherichia coli.
In the SUMO-liraglutide-derived peptide system, mRNA stabilization was also pronounced, and the increase in specific cellular fusion-protein content reached approximately 3-fold (p < 0.001, n = 6).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Across eight reviews evaluating bone and fracture outcomes, liraglutide was reported to improve markers of bone formation.
Research context only—not evidence of a treatment effect.
- Glucagon-Like Peptide-1 Receptor Agonists in Orthopedics: A Scoping Review of Emerging Applications.
Eight reviews assessed bone and fracture outcomes, showing that liraglutide reduced fracture risk and improved bone formation markers, while exenatide had mixed effects.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In an agitation-stress setting, analytical readouts (SEC and CD) indicated that adding PS80 or PX188 increased liraglutide aggregation and altered its conformation; PS80 accelerated aggregation relative to PX188.
Research context only—not evidence of a treatment effect.
- Impact of surfactants on the stability of therapeutic peptides under interfacial stress.
For liraglutide, which forms dynamic oligomers that are not intrinsically stable under agitation stress, SEC and CD reveal extensive aggregation and structural rearrangement in the presence of both PS80 and PX188, with PS80 driving more rapid aggregation.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the authors’ conclusion, comparative risks of retinopathy, albuminuria, and reduced GFR were similar between once-daily liraglutide and once-weekly dulaglutide.
Research context only—not evidence of a treatment effect.
- Comparison between liraglutide and dulaglutide on the incidence or progression of eye and kidney complications.
Our study showed that once-daily liraglutide and once-weekly dulaglutide have similar risks for retinopathy, albuminuria, and reduced GFR.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Media conditioned by liraglutide-pretreated peritoneal macrophages was reported to inhibit pyroptosis-associated protein expression in H9c2 cells.
Research context only—not evidence of a treatment effect.
- pubmed-42242503
Conditioned medium (CM) from Lira-pretreated peritoneal macrophages (PMs) inhibited the expression of pyroptosis-related proteins in H9c2 cells.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Applying principal component analysis (PCA) to spectral data supported multivariate discrimination of samples exposed to different stress conditions via clustering/classification.
Research context only—not evidence of a treatment effect.
- pubmed-42330703
The application of principal component analysis (PCA) enabled the identification of clustering patterns and classification of samples under different stress conditions, while the analysis of loading and contribution line plots allowed recognition of the main spectral features contributing most to the variance.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a cell-culture setup, secreted factors in conditioned medium from liraglutide-pretreated peritoneal macrophages decreased pyroptosis-marker protein expression in H9c2 cells.
Research context only—not evidence of a treatment effect.
- pubmed-42242503
Conditioned medium (CM) from Lira-pretreated peritoneal macrophages (PMs) inhibited the expression of pyroptosis-related proteins in H9c2 cells.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Under the study’s experimental constraints (short incubation; dry film potentially affecting conformation), measurable spectral/structural changes corresponding to early vs advanced degradation phases were still observed in the peptide formulations containing liraglutide.
Research context only—not evidence of a treatment effect.
- pubmed-42330703
Despite the relatively short incubation times and using a dry film approach which may introduce conformational changes, clear changes associated with early and advanced phases of degradation were detected.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Mitochondrial membrane potential, assessed by the JC-1 red/green fluorescence ratio, was reported as restored to 71.5% of the control level with the system.
Research context only—not evidence of a treatment effect.
- Oral Janus nanomotor covalent conjugation rapeseed protein-derived DPP-IV inhibitory peptide and liraglutide: A self-propelled targeted delivery system for promoting insulin secretion and glucose-lowering.
and restored mitochondrial membrane potential (JC-1 red/green fluorescence ratio) to 71.5% of the control level.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A meta-analysis subgroup estimate found that liraglutide 3.0 mg discontinuation was followed by an average 4.83% body-weight regain between treatment end and follow-up, based on 4 studies (95% CI: 3.87-5.79).
Research context only—not evidence of a treatment effect.
- Post-cessation Weight Regain After Weight Management Medications: A Systematic Review and Meta-Analysis.
Subgroup analysis by drug class yielded: semaglutide 2.4 mg, 7.19% (k = 6; 95% CI: 6.42-7.96); liraglutide 3.0 mg, 4.83% (k = 4; 95% CI: 3.87-5.79); and tirzepatide, 13.04% (k = 3; 95% CI: 11.87-14.21).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The LEAD program is reported to show liraglutide improves glycemic control (hyperglycemia control) when used as monotherapy or combined with other antidiabetic medications, with A1C reductions reported up to 1.6%.
Research context only—not evidence of a treatment effect.
- Liraglutide: a review of the first once-daily GLP-1 receptor agonist.
The Liraglutide Effect and Action in Diabetes (LEAD) program demonstrated that liraglutide, when used alone or in combination with other antidiabetic medications, effectively controls hyperglycemia (glycosylated hemoglobin [A1C] reductions up to 1.6%)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The nanomotor delivery system was reported to reduce intracellular oxidative stress by scavenging reactive oxygen species, with an 89.74% scavenging rate.
Research context only—not evidence of a treatment effect.
- Oral Janus nanomotor covalent conjugation rapeseed protein-derived DPP-IV inhibitory peptide and liraglutide: A self-propelled targeted delivery system for promoting insulin secretion and glucose-lowering.
The system effectively scavenged intracellular reactive oxygen species (ROS) with an 89.74% scavenging rate
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Across studies summarized in this narrative review, GLP-1 receptor agonists (including liraglutide) are associated with meaningful body-weight reduction primarily from fat mass, with a reported 20-30% contribution of lean-mass loss to total weight loss.
Research context only—not evidence of a treatment effect.
- Incretin-Based Therapies in Sports: Pharmacological Mechanisms, Performance-Enhancing Potential, and Anti-Doping Implications-A Narrative Review.
GLP-1 RAs (semaglutide, liraglutide, tirzepatide, exenatide) induce substantial weight loss (predominantly fat mass) but also reduce lean mass by 20-30% of total weight loss.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Across eight reviews evaluating bone and fracture outcomes, liraglutide was reported to lower fracture risk.
Research context only—not evidence of a treatment effect.
- Glucagon-Like Peptide-1 Receptor Agonists in Orthopedics: A Scoping Review of Emerging Applications.
Eight reviews assessed bone and fracture outcomes, showing that liraglutide reduced fracture risk and improved bone formation markers, while exenatide had mixed effects.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The reported proteomic effect includes suppression of MSTN with a log₂ fold change of -0.41 and p = 1.7 × 10-6.
Research context only—not evidence of a treatment effect.
- Proteomic effects of short-term liraglutide vs. placebo in a blinded crossover RCT: Implications for efficacy, safety, and comparison with semaglutide.
Myostatin (MSTN) was strongly suppressed (log₂ fold change -0.41; p = 1.7 × 10-6)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The review describes liraglutide as a medicine developed for clinical management of obesity and diabetes.
Research context only—not evidence of a treatment effect.
- Incretin-Based Therapies in Obesity-Related Obstructive Sleep Apnea: A Narrative Review of Evidence Tiers and Mechanistic Plausibility.
Newer medicines such as liraglutide and tirzepatide were developed for obesity and diabetes care
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In ChEMBL, liraglutide is indexed under the identifier CHEMBL4084119.
Research context only—not evidence of a treatment effect.
- LIRAGLUTIDE
ChEMBL ID: CHEMBL4084119
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
ChEMBL lists the preferred molecule name for CHEMBL4084119 as LIRAGLUTIDE.
Research context only—not evidence of a treatment effect.
- LIRAGLUTIDE
Preferred name: LIRAGLUTIDE
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Proteomic measurements were performed on plasma and serum using SomaScan v4.1, covering 6249 proteins.
Research context only—not evidence of a treatment effect.
- Proteomic effects of short-term liraglutide vs. placebo in a blinded crossover RCT: Implications for efficacy, safety, and comparison with semaglutide.
Plasma and serum samples underwent SomaScan v4.1 profiling of 6249 proteins.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The stated framework is that liraglutide has metabolic state-dependent mechanisms: central tanycyte-mediated actions in healthy states, peripheral direct islet actions in glucose intolerance, and insulin-independent mechanisms that maintain efficacy across metabolic states.
Research context only—not evidence of a treatment effect.
- pubmed-42350670
Liraglutide operates through complementary, metabolic state-dependent pathways: tanycyte-mediated brain actions predominate in healthy conditions, direct islet effects emerge during glucose intolerance and insulin-independent mechanisms maintain efficacy across metabolic states.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Within the study’s interpretation, enhanced cardioprotection is attributed to simultaneously addressing iron overload and antioxidant signaling, consistent with the combined liraglutide–deferoxamine approach tested.
Research context only—not evidence of a treatment effect.
- Synergistic cardioprotection by liraglutide and deferoxamine against doxorubicin-induced cardiotoxicity via modulation of ACSL-4/Nrf-2/GPX-4 signaling.
These findings demonstrate that simultaneous targeting of iron overload and antioxidant signaling confers enhanced cardioprotection against Dox-induced injury.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Gut bacterial community profiling used 16S rRNA gene sequencing, yielding 7.1 million sequences via Illumina paired-end reads.
Research context only—not evidence of a treatment effect.
- Effects of liraglutide on gut bacterial community dynamics.
For bacterial community analysis, 7.1 million 16S rRNA gene sequences were retrieved using Illumina paired-end sequencing.
Safety + tolerability
Risks, organized for scanning.
Labels warn about thyroid C-cell tumors observed in rodents; human relevance is unknown. [1]Regulatory labelVictoza prescribing informationDailyMed label for liraglutide marketed as Victoza.
Contraindications
- Medullary thyroid carcinoma history
- MEN 2
- Serious hypersensitivity
Common effects
- Nausea
- Diarrhea
- Vomiting
- Decreased appetite
- Dyspepsia
- Constipation
Serious risks
- Pancreatitis
- Gallbladder disease
- Hypoglycemia with selected therapies
- Kidney injury from dehydration
- Heart-rate increase
Structured from current product labeling [1]Regulatory labelVictoza prescribing informationDailyMed label for liraglutide marketed as Victoza.
Products + regulatory context
Same ingredient. Different records.
| Product | Form | Profile scope | Record |
|---|---|---|---|
| Victoza | Daily subcutaneous injection | Type 2 diabetes and specified cardiovascular risk reduction. | [1]Regulatory labelVictoza prescribing informationDailyMed label for liraglutide marketed as Victoza. |
| Saxenda | Daily subcutaneous injection | Chronic weight management in specified populations. | [16]Published evidence snapshotThese highlights do not include all the information needed to use SAXENDA®safely and effectively. See full prescribing information for SAXENDA.SAXENDA (liraglutide) injection, for subcutaneous useInitial U.S. Approval: 2010dailymed · T1 |
Do not infer dosing, interchangeability, or an approved use from the ingredient name alone. Open the current label for the exact product and presentation.
Administration, interactions + monitoring
The practical clinical context.
- Administration boundary
- Once-daily subcutaneous injection with product-specific titration. [1]Regulatory labelVictoza prescribing informationDailyMed label for liraglutide marketed as Victoza.
Research status + gaps
What still needs better answers.
1616 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (988), assurance_score_below_0.72 (500), current_regulatory_source_required (327), evidence_scope (440), extraction_ambiguity (1009), extraction_confidence_not_high (1), high_risk_requires_regulatory_or_two_independent_sources (576), no_direct_support (1484), proposal_not_staged (37)
How Peplexicon reads evidence
- Authority
- What kind of source is making the statement?
- Independence
- Do multiple citations represent separate studies—or the same evidence repeated?
- Directness
- Does the population, product, dose, outcome, and time horizon match the claim?
- Consistency
- Do credible sources support, qualify, or contradict one another?
References + discovery
Open the records yourself.
- 1Regulatory labelVictoza prescribing informationOpen ↗
DailyMed label for liraglutide marketed as Victoza.
- 2Literature indexEvery PubMed result for liraglutideOpen ↗
Live National Library of Medicine literature search; results are not pre-screened or deduplicated.
- 3Trial registryEvery registered study for liraglutideOpen ↗
Live ClinicalTrials.gov search, including completed, active, and historical records.
- 4Chemical recordliraglutide chemical recordOpen ↗
PubChem compound search from the National Library of Medicine.
- 5Published evidence snapshotChEMBL activities for CHEMBL4084119Open ↗
chembl-activities · T6
Published 2026-08-21 · retrieved 2026-08-21T17:03:42Z - 6Published evidence snapshotLIRAGLUTIDEOpen ↗
chembl-molecule · T6
Published 2026-08-21 · retrieved 2026-08-21T17:03:42Z - 7Published evidence snapshotThese highlights do not include all the information needed to use LIRAGLUTIDE INJECTION safely and effectively. See full prescribing information for LIRAGLUTIDE INJECTION.LIRAGLUTIDE injection, for subcutaneous useInitial U.S. Approval: 2010Open ↗
dailymed · T1
Published 2025-11-13 · retrieved 2026-08-28T12:18:09Z - 8Published evidence snapshotThese highlights do not include all the information needed to use LIRAGLUTIDE INJECTION safely and effectively. See full prescribing information for LIRAGLUTIDE INJECTION.LIRAGLUTIDE injection, for subcutaneous useInitial U.S. Approval: 2010Open ↗
dailymed · T1
Published 2025-10-16 · retrieved 2026-08-28T12:18:09Z - 9Published evidence snapshotThese highlights do not include all the information needed to useLIRAGLUTIDE INJECTIONsafely and effectively. See full prescribing information forLIRAGLUTIDE INJECTION.LIRAGLUTIDE injection, for subcutaneous useInitial U.S. Approval:2010Open ↗
dailymed · T1
Published 2025-01-30 · retrieved 2026-09-01T08:37:10Z - 10Published evidence snapshotThese highlights do not include all the information needed to use LIRAGLUTIDE INJECTION safely and effectively. See full prescribing information for LIRAGLUTIDE INJECTION.LIRAGLUTIDE injection, for subcutaneous useInitial U.S. Approval: 2010Open ↗
dailymed · T1
Published 2026-07-27 · retrieved 2026-08-21T17:03:42Z - 11Published evidence snapshotThese highlights do not include all the information needed to useLIRAGLUTIDE INJECTIONsafely and effectively. See full prescribing information forLIRAGLUTIDE INJECTION.LIRAGLUTIDE injection, for subcutaneous useInitial U.S. Approval:2010Open ↗
dailymed · T1
Published 2026-01-30 · retrieved 2026-08-28T12:18:09Z - 12Published evidence snapshotThese highlights do not include all the information needed to use VICTOZA safely and effectively. See full prescribing information for VICTOZA.VICTOZA®(liraglutide) injection, for subcutaneous useInitial U.S. Approval: 2010Open ↗
dailymed · T1
Published 2023-02-06 · retrieved 2026-09-05T08:43:42Z - 13Published evidence snapshotThese highlights do not include all the information needed to use LIRAGLUTIDE INJECTION safely and effectively. See full prescribing information for LIRAGLUTIDE INJECTION.LIRAGLUTIDE injection, for subcutaneous useInitial U.S. Approval: 2010Open ↗
dailymed · T1
Published 2026-05-14 · retrieved 2026-08-18T22:03:15Z - 14Published evidence snapshotThese highlights do not include all the information needed to use LIRAGLUTIDE INJECTION safely and effectively. See full prescribing information for LIRAGLUTIDE INJECTION.LIRAGLUTIDE injection, for subcutaneous useInitial U.S. Approval: 2010Open ↗
dailymed · T1
Published 2026-06-18 · retrieved 2026-08-21T17:03:42Z - 15Published evidence snapshotThese highlights do not include all the information needed to use VICTOZA safely and effectively. See full prescribing information for VICTOZA.VICTOZA®(liraglutide) injection, for subcutaneous useInitial U.S. Approval: 2010Open ↗
dailymed · T1
Published 2023-02-06 · retrieved 2026-09-05T08:43:42Z - 16Published evidence snapshotThese highlights do not include all the information needed to use SAXENDA®safely and effectively. See full prescribing information for SAXENDA.SAXENDA (liraglutide) injection, for subcutaneous useInitial U.S. Approval: 2010Open ↗
dailymed · T1
Published 2026-02-25 · retrieved 2026-08-18T22:03:08Z - 17Published evidence snapshotThese highlights do not include all the information needed to use LIRAGLUTIDE INJECTION safely and effectively. See full prescribing information for LIRAGLUTIDE INJECTION.LIRAGLUTIDE injection, for subcutaneous useInitial U.S. Approval: 2010Open ↗
dailymed · T1
Published 2026-06-24 · retrieved 2026-08-21T17:03:42Z - 18Published evidence snapshotThese highlights do not include all the information needed to use VICTOZA®safely and effectively. See full prescribing information for VICTOZA.VICTOZA (liraglutide) injection, for subcutaneous useInitial U.S. Approval: 2010Open ↗
dailymed · T1
Published 2025-10-14 · retrieved 2026-08-18T22:03:20Z - 19Published evidence snapshotThese highlights do not include all the information needed to useLIRAGLUTIDE INJECTION safely and effectively. See full prescribing information for LIRAGLUTIDE INJECTION.LIRAGLUTIDE injection, for subcutaneous useInitial U.S. Approval: 2010Open ↗
dailymed · T1
Published 2026-02-27 · retrieved 2026-08-25T08:39:52Z - 20Published evidence snapshotThese highlights do not include all the information needed to use SAXENDA®safely and effectively. See full prescribing information for SAXENDA.SAXENDA (liraglutide) injection, for subcutaneous useInitial U.S. Approval: 2010Open ↗
dailymed · T1
Published 2024-01-26 · retrieved 2026-09-01T10:53:41Z - 21Published evidence snapshotThese highlights do not include all the information needed to use LIRAGLUTIDE INJECTION safely and effectively. See full prescribing information for LIRAGLUTIDE INJECTION.LIRAGLUTIDE injection, for subcutaneous useInitial U.S. Approval: 2010Open ↗
dailymed · T1
Published 2026-01-12 · retrieved 2026-08-28T12:18:09Z - 22Published evidence snapshotThese highlights do not include all the information needed to use LIRAGLUTIDE INJECTION safely and effectively. See full prescribing information for LIRAGLUTIDE INJECTION.LIRAGLUTIDE injection, for subcutaneous useInitial U.S. Approval: 2010Open ↗
dailymed · T1
Published 2026-03-12 · retrieved 2026-08-28T12:18:09Z - 23Published evidence snapshotThese highlights do not include all the information needed to use LIRAGLUTIDE INJECTION safely and effectively. See full prescribing information for LIRAGLUTIDE INJECTION.LIRAGLUTIDE injection, for subcutaneous useInitial U.S. Approval: 2010Open ↗
dailymed · T1
Published 2025-10-10 · retrieved 2026-08-25T08:39:52Z - 24Published evidence snapshotThese highlights do not include all the information needed to use LIRAGLUTIDE INJECTION safely and effectively. See full prescribing information for LIRAGLUTIDE INJECTION.LIRAGLUTIDE injection, for subcutaneous useInitial U.S. Approval: 2010Open ↗
dailymed · T1
Published 2026-04-16 · retrieved 2026-08-25T08:39:52Z - 25Published evidence snapshotA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.Open ↗
doi · T2
Published 2015-07-01 · retrieved 2026-08-25T11:02:54Z - 26Published evidence snapshotLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes.Open ↗
doi · T2
Published 2016-06-13 · retrieved 2026-09-08T21:45:53Z - 27Published evidence snapshotLiraglutide STADA | European Medicines Agency (EMA)Open ↗
ema · T6
Published 2026-08-18 · retrieved 2026-08-18T22:03:03Z - 28Published evidence snapshotSaxenda | European Medicines Agency (EMA)Open ↗
ema · T6
Published 2026-08-18 · retrieved 2026-08-18T22:03:11Z - 29Published evidence snapshotVictoza | European Medicines Agency (EMA)Open ↗
ema · T6
Published 2026-08-18 · retrieved 2026-08-18T22:03:13Z - 30Published evidence snapshotIUPHAR ligand commentaryOpen ↗
iuphar-comments · T6
Published 2026-08-21 · retrieved 2026-08-21T17:03:42Z - 31Published evidence snapshotLiraglutide: a review of the first once-daily GLP-1 receptor agonist.Open ↗
pubmed · T3
Published 2011-03-01 · retrieved 2026-09-09T18:01:27Z - 32Published evidence snapshotLiraglutide and obesity: a review of the data so far.Open ↗
pubmed · T3
Published 2015-01-01 · retrieved 2026-09-09T18:01:27Z - 33Published evidence snapshotProteomic effects of short-term liraglutide vs. placebo in a blinded crossover RCT: Implications for efficacy, safety, and comparison with semaglutide.Open ↗
pubmed · T2
Published 2026-04-01 · retrieved 2026-08-18T22:03:06Z - 34Published evidence snapshotGlucagon-like peptide-1 receptor agonists reduce experimental atherosclerosis progression, inflammatory biomarkers and cardiovascular events, irrespective of hyperglycaemia and obesity.Open ↗
pubmed · T3
Published 2026-07-21 · retrieved 2026-09-09T08:36:24Z - 35Published evidence snapshotUse of Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study.Open ↗
pubmed · T3
Published 2026-07-01 · retrieved 2026-09-01T08:37:10Z - 36Published evidence snapshotpubmed-42002107Open ↗
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-17T23:05:51Z - 37Published evidence snapshotThe glucagon-like peptide-1 receptor agonist, Ex4, reduces intromission in sexually experienced male mice.Open ↗
pubmed · T3
Published 2026-07-01 · retrieved 2026-08-28T12:18:09Z - 38Published evidence snapshotBeyond weight loss: multisystem benefits of obesity medications.Open ↗
pubmed · T3
Published 2026-08-01 · retrieved 2026-08-21T08:29:16Z - 39Published evidence snapshotpubmed-42242503Open ↗
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-17T23:05:51Z - 40Published evidence snapshotRisk of Age-Related Ocular Diseases in Non-Diabetic Adults With Obesity Using Glucagon-Like Peptide 1 Receptor Agonists.Open ↗
pubmed · T3
Published 2026-08-01 · retrieved 2026-09-09T08:36:24Z - 41Published evidence snapshotComparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes.Open ↗
pubmed · T3
Published 2026-09-01 · retrieved 2026-09-05T08:30:31Z - 42Published evidence snapshotComparative Effects of Antidiabetic Drugs on Body Composition: A Systematic Review and Network Meta-Analysis.Open ↗
pubmed · T2
Published 2026-09-01 · retrieved 2026-09-09T08:33:27Z - 43Published evidence snapshotpubmed-42330703Open ↗
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-17T23:02:04Z - 44Published evidence snapshotpubmed-42337176Open ↗
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-17T23:05:51Z - 45Published evidence snapshotGLP-1 receptor agonism reduces PTSD-like anxiety and alters amygdala-hippocampal activity patterns in a Chemogenetic mouse model.Open ↗
pubmed · T3
Published 2026-07-13 · retrieved 2026-09-09T08:36:24Z - 46Published evidence snapshotpubmed-42350670Open ↗
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-17T23:05:51Z - 47Published evidence snapshotAssessing the risk of diabetic retinopathy progression with GLP-1 receptor agonists: a systematic review and meta-analysis.Open ↗
pubmed · T2
Published 2026-06-30 · retrieved 2026-08-25T22:30:24Z - 48Published evidence snapshotLiraglutide combined with dapagliflozin treatment improves myocardial disease and endothelial dysfunction in T2DM mice.Open ↗
pubmed · T3
Published 2026-09-01 · retrieved 2026-09-05T08:43:42Z - 49Published evidence snapshotGlucagon-like peptide-1 receptor agonists for weight management in mental illness: a network meta-analysis.Open ↗
pubmed · T2
Published 2026-07-08 · retrieved 2026-08-25T08:39:52Z - 50Published evidence snapshotPatterns of Use for GLP-1 Receptor Agonists in a Weight Management Cohort: A Military Health System Database Analysis of Active Duty Service Members From 2021 to 2025.Open ↗
pubmed · T3
Published 2026-07-09 · retrieved 2026-08-24T08:31:35Z - 51Published evidence snapshotGLP-1 Receptor Agonists and Fertility: What Is Known So Far?Open ↗
pubmed · T3
Published 2026-07-01 · retrieved 2026-09-11T08:35:08Z - 52Published evidence snapshotOptimal Timing for Initiating Liraglutide 3.0 mg in Patients With Persistent Obesity Six Months After Metabolic and Bariatric Surgery.Open ↗
pubmed · T3
Published 2026-08-01 · retrieved 2026-08-25T08:39:52Z - 53Published evidence snapshotComparative Outcomes of Metabolic and Bariatric Surgery Versus GLP-1 Receptor Agonists: An Updated Systematic Review and Meta-Analysis of 14,548 Patients.Open ↗
pubmed · T3
Published 2026-07-14 · retrieved 2026-09-09T08:36:24Z - 54Published evidence snapshotVutiglabridin overcomes the GLP-1 RA-associated weight-loss plateau to achieve normal body weight.Open ↗
pubmed · T3
Published 2026-07-15 · retrieved 2026-08-25T08:39:52Z - 55Published evidence snapshotSemaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data.Open ↗
pubmed · T3
Published 2026-07-16 · retrieved 2026-09-09T08:36:24Z - 56Published evidence snapshotSynergistic cardioprotection by liraglutide and deferoxamine against doxorubicin-induced cardiotoxicity via modulation of ACSL-4/Nrf-2/GPX-4 signaling.Open ↗
pubmed · T3
Published 2026-07-18 · retrieved 2026-09-09T08:36:24Z - 57Published evidence snapshotGlucagon-Like Peptide-1 Receptor Agonists in Orthopedics: A Scoping Review of Emerging Applications.Open ↗
pubmed · T3
Published 2026-07-01 · retrieved 2026-08-28T12:18:09Z - 58Published evidence snapshotGLP-1 receptor agonists in Parkinson's disease: a meta-analysis revealing motor benefit and highlighting mood improvement.Open ↗
pubmed · T2
Published 2026-01-01 · retrieved 2026-09-01T08:37:10Z - 59Published evidence snapshotpubmed-42494804Open ↗
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-17T23:05:51Z - 60Published evidence snapshotCirculating levels of PYY are increased in individuals with bile acid diarrhoea.Open ↗
pubmed · T3
Published 2026-07-24 · retrieved 2026-09-09T08:36:24Z - 61Published evidence snapshotComparison between liraglutide and dulaglutide on the incidence or progression of eye and kidney complications.Open ↗
pubmed · T3
Published 2026-07-25 · retrieved 2026-09-09T08:36:24Z - 62Published evidence snapshotpubmed-42500463Open ↗
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-17T23:05:51Z - 63Published evidence snapshotChanges in the Adrenal Cortex Induced by Liraglutide Treatment and Exercise in a Rat Model of Menopausal Transition.Open ↗
pubmed · T3
Published 2026-07-13 · retrieved 2026-09-09T08:36:24Z - 64Published evidence snapshotIncretin-Based Therapies in Sports: Pharmacological Mechanisms, Performance-Enhancing Potential, and Anti-Doping Implications-A Narrative Review.Open ↗
pubmed · T3
Published 2026-07-08 · retrieved 2026-08-24T08:31:35Z - 65Published evidence snapshotTirzepatide Attenuates Wire Injury-Induced Arterial Remodeling in Non-Diabetic and Diabetic Mice: Comparison with Semaglutide.Open ↗
pubmed · T3
Published 2026-07-11 · retrieved 2026-08-23T08:27:39Z - 66Published evidence snapshotOral Health Implications of GLP-1 Receptor Agonists and Other Incretin-Based Therapies.Open ↗
pubmed · T3
Published 2026-07-09 · retrieved 2026-08-24T08:31:35Z - 67Published evidence snapshotPost-cessation Weight Regain After Weight Management Medications: A Systematic Review and Meta-Analysis.Open ↗
pubmed · T3
Published 2026-06-01 · retrieved 2026-08-26T08:30:34Z - 68Published evidence snapshotEffects of liraglutide on gut bacterial community dynamics.Open ↗
pubmed · T3
Published 2026-09-01 · retrieved 2026-09-05T08:43:42Z - 69Published evidence snapshotSafety and Efficacy of Glucagon Like Peptide-1 Receptor Agonism-Based Therapies in End-Stage Renal Disease: A Systematic Review and Meta-Analysis.Open ↗
pubmed · T3
Published 2026-08-04 · retrieved 2026-08-21T17:03:42Z - 70Published evidence snapshotA clinical and experimental investigation of liraglutide effects on the brain-kidney axis.Open ↗
pubmed · T3
Published 2026-08-07 · retrieved 2026-08-21T17:03:42Z - 71Published evidence snapshotPharmacotherapy in obstructive sleep apnoea: a clinical guide.Open ↗
pubmed · T3
Published 2026-08-06 · retrieved 2026-08-20T08:28:52Z - 72Published evidence snapshotAnalysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis.Open ↗
pubmed · T3
Published 2026-08-06 · retrieved 2026-08-18T20:56:12Z - 73Published evidence snapshotpubmed-42565180Open ↗
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-17T23:02:04Z - 74Published evidence snapshotA GLP-1 receptor agonist enhances islet microvascular flow through nitric oxide-dependent mechanisms in a diabetic mouse model: investigation using intravital two-photon imaging.Open ↗
pubmed · T3
Published 2026-08-07 · retrieved 2026-08-21T17:03:42Z - 75Published evidence snapshotTrends in glucagon-like peptide-1 receptor agonist utilization and expenditure in Croatia.Open ↗
pubmed · T3
Published 2026-08-01 · retrieved 2026-08-19T08:29:05Z - 76Published evidence snapshotRisk of Dementia after initiation of GLP-1 RA versus long-acting insulin in patients with type 2 Diabetes mellitus.Open ↗
pubmed · T3
Published 2026-08-08 · retrieved 2026-08-21T17:03:42Z - 77Published evidence snapshotAssociation of Glucagon-Like Peptide-1 Receptor Analogues and Laryngeal Symptoms in Obese Adults.Open ↗
pubmed · T3
Published 2026-08-12 · retrieved 2026-08-17T23:05:51Z - 78Published evidence snapshotSemaglutide and Liraglutide Modulate Oxidative Stress and Wound Repair in Normal Human Skin Cells Exposed to an In Vitro Diabetic-like Environment.Open ↗
pubmed · T3
Published 2026-08-03 · retrieved 2026-08-18T20:56:12Z - 79Published evidence snapshotAnti-Obesity Medications in Longevity and Aesthetic Medicine.Open ↗
pubmed · T3
Published 2026-08-03 · retrieved 2026-08-18T20:56:12Z - 80Published evidence snapshotIncretin-Based Therapies in Obesity-Related Obstructive Sleep Apnea: A Narrative Review of Evidence Tiers and Mechanistic Plausibility.Open ↗
pubmed · T3
Published 2026-01-01 · retrieved 2026-08-18T20:56:12Z - 81Published evidence snapshotpubmed-42595520Open ↗
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-17T23:05:51Z - 82Published evidence snapshotInfluence of GLP-1 Receptor Agonists on Surgical and Nonsurgical Treatment of Ankle Osteoarthritis.Open ↗
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-18T20:01:53Z - 83Published evidence snapshotEngineering 3'-UTR hairpin structures to modulate mRNA stability and recombinant protein production in Escherichia coli.Open ↗
pubmed · T3
Published 2026-08-31 · retrieved 2026-09-05T08:43:42Z - 84Published evidence snapshotImpact of surfactants on the stability of therapeutic peptides under interfacial stress.Open ↗
pubmed · T3
Published 2026-09-02 · retrieved 2026-09-11T08:35:08Z - 85Published evidence snapshotTrends in preoperative weight loss modalities among patients receiving body contouring surgery.Open ↗
pubmed · T3
Published 2026-08-09 · retrieved 2026-09-05T08:30:31Z - 86Published evidence snapshotAn Orthogonal Framework for Higher-Order Structural and In Vitro Functional Comparability of Chemically Synthesized Liraglutide Relative to an rDNA-Origin Reference Product.Open ↗
pubmed · T3
Published 2026-09-03 · retrieved 2026-09-05T08:43:42Z - 87Published evidence snapshotGLP1-RA Use and Risk of Non-arteritic Anterior Ischemic Optic Neuropathy in Patients with Type 2 Diabetes.Open ↗
pubmed · T3
Published 2026-09-03 · retrieved 2026-09-05T08:43:42Z - 88Published evidence snapshotGlucagon-like Peptide-1 Receptor Agonist-Associated Injection Site and Dermatologic Reactions.Open ↗
pubmed · T3
Published 2026-09-03 · retrieved 2026-09-05T08:30:31Z - 89Published evidence snapshotOral Janus nanomotor covalent conjugation rapeseed protein-derived DPP-IV inhibitory peptide and liraglutide: A self-propelled targeted delivery system for promoting insulin secretion and glucose-lowering.Open ↗
pubmed · T3
Published 2026-11-01 · retrieved 2026-09-05T08:43:42Z - 90Published evidence snapshotSafety and Glycemic Efficacy of Perioperative Liraglutide in Cardiac Surgery: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Open ↗
pubmed · T3
Published 2026-09-04 · retrieved 2026-09-05T08:43:42Z - 91Published evidence snapshotLiraglutide Attenuates Hepatocyte Ferroptosis in an In Vitro Model of Metabolic Dysfunction-Associated Steatotic Liver Disease.Open ↗
pubmed · T3
Published 2026-09-04 · retrieved 2026-09-05T08:43:42Z